In patients with non-small cell lung cancer, the proportion of MDSCs in tumor tissue fell after thymalfasin treatment.
In plain wordsIn people with lung cancer, thymalfasin treatment lowered the share of immune-suppressing MDSC cells in tumor tissue compared with before treatment.
- Peptide
- Thymosin alpha-1
- Outcome
- DecreaseHLA-DR-CD14-CD33+ MDSC proportion in tumor tissue
- Study
n = 50
- Comparator
- Before treatment
- Outcome group
- Immune response · Cancer
- Studied dose
- Dose not stated
Measurements
- MDSC proportion
- 1.65%
- before treatment
- MDSC proportion
- 1.15%
- after treatment
Source sentences
The proportion of HLA-DR-CD14-CD33+ MDSCs in the tissues of NSCLC group was 1.65±0.43% before treatment and 1.15±0.50% after treatment (P < 0.05).
2 context sentences(design, population, supporting numbers)
50 cases of NSCLC (NSCLC group) diagnosed in Chest Hospital of Jiangxi Province were selected as the research subjects, and 50 healthy subjects who underwent physical examination in our hospital during the same period were selected as the healthy control group.
The expression of HLA-DR-CD14-CD33+ MDSCs in peripheral blood mononuclear cells and tumor tissue single cell suspension of NSCLC patients before and after thymalfasin treatment was explored by flow cytometry.